These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15757962)

  • 1. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.
    Spoorenberg A; van Tubergen A; Landewé R; Dougados M; van der Linden S; Mielants H; van de Tempel H; van der Heijde D
    Rheumatology (Oxford); 2005 Jun; 44(6):789-95. PubMed ID: 15757962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
    Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
    Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.
    Calin A; Nakache JP; Gueguen A; Zeidler H; Mielants H; Dougados M
    J Rheumatol; 1999 Apr; 26(4):975-9. PubMed ID: 10229431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The BASDAI-D--an instrument to defining disease status in ankylosing spondylitis and related diseases].
    Bönisch A; Ehlebracht-König I
    Z Rheumatol; 2003 Jun; 62(3):251-63. PubMed ID: 12827402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
    Maksymowych WP; Richardson R; Mallon C; van der Heijde D; Boonen A
    Arthritis Rheum; 2007 Feb; 57(1):133-9. PubMed ID: 17266072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments.
    Østensen M; Fuhrer L; Mathieu R; Seitz M; Villiger PM
    Ann Rheum Dis; 2004 Oct; 63(10):1212-7. PubMed ID: 15361373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):961-5. PubMed ID: 10229428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient utilities in ankylosing spondylitis and the association with other outcome measures.
    Bakker C; Rutten-van Mölken M; Hidding A; van Doorslaer E; Bennett K; van der Linden S
    J Rheumatol; 1994 Jul; 21(7):1298-304. PubMed ID: 7966073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis].
    Grazio S; Grubisić F; Nemcić T; Matijević V; Skala H
    Reumatizam; 2009; 56(2):63-76. PubMed ID: 20429263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
    Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
    Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.
    Landewé R; Rump B; van der Heijde D; van der Linden S
    Ann Rheum Dis; 2004 May; 63(5):530-4. PubMed ID: 15082483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six months open label trial of leflunomide in active ankylosing spondylitis.
    Haibel H; Rudwaleit M; Braun J; Sieper J
    Ann Rheum Dis; 2005 Jan; 64(1):124-6. PubMed ID: 15608310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Romanian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) in patients with spondylarthropathies.
    Udrea G; Ciobanu C; Mihai C; Stoica V; Suteanu S; van der Heijde D; van der Linden S
    Rom J Intern Med; 2004; 42(1):199-209. PubMed ID: 15529610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index.
    Heuft-Dorenbosch L; van Tubergen A; Spoorenberg A; Landewé R; Dougados M; Mielants H; van der Tempel H; van der Heijde D
    Arthritis Rheum; 2004 Apr; 51(2):154-9. PubMed ID: 15077254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.